Is Wegovy Covered by Insurance? (2026)

Direct Answer: It Depends on Your Plan

It depends on which insurance you have. For pricing without coverage, see Wegovy without insurance. Medicare Part D covers Wegovy in 2026 for enrollees with established cardiovascular disease. Most fully insured commercial plans cover it when obesity is included as a covered indication, but many self-funded employer plans exclude anti-obesity drugs under ERISA. ACA marketplace plans have no federal mandate to cover it. Medicaid coverage varies by state with no uniform national requirement.

Medicare Part D Coverage of Wegovy in 2026

Medicare Part D coverage of Wegovy started in 2024 following a CMS coverage determination that recognized semaglutide 2.4 mg as a drug used for treatment of a disease rather than purely for weight loss. The coverage is tied to the cardiovascular indication approved by the FDA in March 2024: reducing the risk of serious cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight who already have established cardiovascular disease.

In practical terms, the patient must have a documented prior heart attack, stroke, or peripheral artery disease diagnosis. Obesity alone, without the cardiovascular history, does not trigger Medicare Part D coverage in 2026. Prior authorization is required by most Part D plans, and Wegovy is typically placed on a specialty tier with higher cost-sharing. The 2026 Medicare Part D out-of-pocket cap of $2,100 limits how much you pay annually regardless of where Wegovy lands on the formulary tier.

Medicare Advantage plans that include integrated Part D drug benefits also cover Wegovy under the same cardiovascular indication, but cost-sharing and formulary tier placement differ by carrier and plan. Compare plans at medicare.gov/plan-compare before the Annual Enrollment Period (October 15 to December 7, 2026) if Wegovy coverage is a priority.

Commercial Insurance Coverage: Fully Insured vs. Self-Funded Plans

Commercial insurance coverage for Wegovy depends on a key distinction: whether the employer offers a fully insured plan (subject to state insurance mandates) or a self-funded plan (governed by ERISA federal law, which preempts state mandates). Roughly 60% of workers at large employers are in self-funded plans, and those employers can exclude anti-obesity medications from their formularies without any state-level recourse.

For fully insured commercial plans, whether Wegovy is covered depends on the employer's benefit design and the state. Some states have passed or proposed mandates to require coverage of GLP-1 receptor agonists for obesity, but as of 2026 no comprehensive federal mandate exists for commercial plans. Plans that cover Wegovy almost always require prior authorization with documentation of BMI at or above 27 with a cardiovascular risk factor or BMI at or above 30, and many require step therapy (demonstrating failure of lifestyle intervention first).

ACA Marketplace Plans and Wegovy in 2026

ACA marketplace plans sold on healthcare.gov and state-based exchanges are not required to cover anti-obesity medications as an Essential Health Benefit in 2026. Weight management counseling is a preventive service required without cost-sharing, but the injectable medication itself is not federally mandated. Some marketplace plans, particularly silver and gold tier plans from certain carriers, voluntarily include GLP-1 drugs on their formulary.

Before enrolling in a marketplace plan, check the plan's Summary of Benefits and Coverage and its drug formulary directly. The Open Enrollment Period for 2026 ACA marketplace coverage ran from November 1, 2025 through January 15, 2026. If you missed open enrollment, a Special Enrollment Period triggered by a qualifying life event (job loss, marriage, birth of a child) is the only way to enroll outside that window. Medicaid has no enrollment window: year-round enrollment is available.

Medicaid Coverage of Wegovy by State

Medicaid has no federal requirement to cover anti-obesity medications for weight management in 2026. See does Medicaid cover GLP-1 by state. States can choose to include Wegovy in their drug benefit, and some do, typically with prior authorization requiring BMI documentation and cardiovascular risk factors. Coverage is more common for the diabetes indication (semaglutide 1 mg as Ozempic) than for the weight management indication (semaglutide 2.4 mg as Wegovy), because federal law excludes drugs used exclusively for weight loss from mandatory Medicaid coverage.

To check whether your state Medicaid program covers Wegovy, call your state Medicaid office or log into your managed care plan's online formulary lookup. Look up the drug under both its brand name (Wegovy) and its generic name (semaglutide), because formulary listings vary. If your state does not cover Wegovy, check whether it covers Ozempic for cardiovascular risk reduction, which may be a clinically appropriate alternative depending on your prescriber's judgment.

Wegovy Cost Without Insurance in 2026 and Savings Options

Wegovy's list price is approximately $1,349 per month in 2026 without insurance or savings programs. Novo Nordisk's NovoCare program offers savings for commercially insured patients who meet eligibility criteria: the savings card can reduce monthly out-of-pocket costs, though the exact amount depends on your plan's cost-sharing and the specific offer terms at the time you apply. Visit novocare.com or ask your pharmacist for the current NovoCare savings card offer. Income thresholds for uninsured patient assistance are not published here because they change; contact NovoCare directly for current program terms.

GoodRx and other pharmacy discount programs can reduce the out-of-pocket price of Wegovy at the pharmacy counter, though specialty injectable drugs often show smaller percentage discounts than oral generics. Check goodrx.com with your ZIP code for current prices at pharmacies near you. Note that GoodRx discounts cannot be combined with insurance benefits in the same transaction: you choose one or the other at the pharmacy.

How to Get Wegovy Covered: Prior Authorization and Appeals

Prior authorization is required by most plans that cover Wegovy. The prescriber typically submits clinical documentation including your BMI, cardiovascular risk factors or established cardiovascular disease diagnosis, and prior treatments tried. The plan's medical director reviews the request against coverage criteria. Approval timelines vary from 24 hours (urgent) to 15 business days (standard). Medicare Part D plans must follow CMS prior authorization timelines.

If your plan denies the prior authorization, you have the right to appeal. For Medicare Part D, the appeal sequence is: Level 1 redetermination (plan reviews again, 7 days standard), Level 2 Independent Review Entity review, then Medicare Appeals Council if needed. For commercial plans, internal appeal then external independent review are the standard path. A denial is not final until you have exhausted the appeal process. Ask your prescriber to provide a detailed letter of medical necessity, citing the SELECT trial cardiovascular outcomes data and your specific cardiovascular risk profile, to support the appeal.

Alternatives If Insurance Does Not Cover Wegovy

If Wegovy is not covered by your plan, several alternatives are worth exploring. First, ask your prescriber whether semaglutide 1 mg weekly (Ozempic) prescribed off-label for weight management might be covered: Ozempic is approved for type 2 diabetes and cardiovascular risk reduction, and some plans cover it even when they exclude the Wegovy formulation. The clinical mechanism is the same drug at a different dose.

Second, liraglutide (Saxenda) is another FDA-approved weight management GLP-1 and may be on a more accessible formulary tier with lower cost-sharing. Third, tirzepatide (Zepbound) is a dual GIP/GLP-1 agonist approved for chronic weight management; it may have different formulary placement than Wegovy on your specific plan. Fourth, for Medicare enrollees whose Part D plan denies Wegovy due to a strict cardiovascular indication requirement, filing an appeal with a letter of medical necessity from a cardiologist is often the most effective path. Fifth, the NovoCare patient support line at 1-833-NOVO-411 can clarify current savings and assistance options for your specific coverage situation.

Does Medicare cover Wegovy in 2026?

Yes, Medicare Part D covers Wegovy in 2026, but only for enrollees with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) plus obesity or overweight. This follows the 2024 CMS coverage decision based on the SELECT trial. Prior authorization is required, and Wegovy is typically on a specialty tier. The 2026 Part D out-of-pocket cap of $2,100 limits your annual exposure.

Does Medicare cover Wegovy for weight loss only (without cardiovascular disease)?

No. Medicare does not cover Wegovy solely for weight loss without an established cardiovascular disease diagnosis in 2026. The statute that historically excluded weight loss drugs from Medicare coverage was only partially overridden by the FDA cardiovascular indication. A cardiologist's documentation of established cardiovascular disease is required to qualify for Medicare Part D coverage.

Does Medicaid cover Wegovy?

It depends on the state. Federal law does not require Medicaid to cover drugs used exclusively for weight loss. Some states voluntarily cover Wegovy with prior authorization; others do not. Coverage of semaglutide for type 2 diabetes (as Ozempic) is more common in Medicaid. Check your state's Medicaid formulary or call your managed care plan's member services line to find out.

How much does Wegovy cost per month without insurance in 2026?

The list price of Wegovy is approximately $1,349 per month in 2026 before any savings programs. The NovoCare savings card from Novo Nordisk can reduce costs for commercially insured patients; visit novocare.com for current offer terms. GoodRx prices at specific pharmacies may be lower than list price; check goodrx.com with your ZIP code. Do not use GoodRx and insurance in the same transaction.

What is the NovoCare savings program for Wegovy?

NovoCare is Novo Nordisk's patient support program for commercially insured patients. The savings card can reduce monthly out-of-pocket costs for eligible patients. Eligibility and the exact savings amount depend on your insurance coverage and current program terms, which can change. Contact NovoCare directly at 1-833-NOVO-411 or novocare.com for current income thresholds and program details for uninsured patients.

Does employer insurance cover Wegovy?

It depends on whether your employer offers a fully insured or self-funded plan. Fully insured plans are subject to state insurance mandates, and many cover Wegovy when obesity is a covered indication. Self-funded ERISA plans, which cover roughly 60% of large-employer workers, can exclude anti-obesity drugs without state oversight. Check your plan's Summary of Benefits and Coverage or call your HR benefits team.

What is the prior authorization process for Wegovy?

Your prescriber submits a prior authorization request with documentation of your BMI, cardiovascular diagnosis or risk factors, and prior treatments. The plan reviews it against coverage criteria, typically within 15 business days for standard requests. If denied, you can appeal. For Medicare Part D, the appeals process runs through plan redetermination, then independent review, then Medicare Appeals Council. Ask your prescriber for a detailed letter of medical necessity citing the SELECT trial to support an appeal.

What are alternatives to Wegovy if insurance won't cover it?

Ask your prescriber about semaglutide 1 mg (Ozempic, same drug lower dose), which may be covered for cardiovascular risk reduction. Liraglutide (Saxenda) and tirzepatide (Zepbound) are other FDA-approved weight management options that may have different formulary placement on your plan. The NovoCare patient support line at 1-833-NOVO-411 can guide you through current savings options. Filing an appeal with a cardiologist's letter of medical necessity is often effective for Medicare Part D denials.